FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma

On May 17, 2016, after an expedited priority review, the U.S. Food and Drug Administration granted accelerated approval to nivolumab for the treatment of patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Kasamon, Yvette L., de Claro, R. Angelo, Wang, Yaping, Shen, Yuan Li, Farrell, Ann T., Pazdur, Richard
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2017
Konular:
Regulatory Issues: FDA
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5423515/
https://ncbi.nlm.nih.gov/pubmed/28438889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0004
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller